This product is a second-generation cephalosporin for intravenous or intramuscular injection. The antibacterial spectrum against Gram-negative bacilli is broader than that of the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.

Extract from the above information

A broad-spectrum third-generation cephalosporin that is very stable to beta-lactamase, widely distributed in body fluids and various organs, with few side effects and good stability. It has strong antibacterial activity against Enterobacteriaceae, and both influenza bacilli and gonococci that produce and do not produce beta-lactamase are highly sensitive to this product. It has stronger antibacterial effects on Escherichia coli, aerogenes, various Proteus species, and influenza bacilli than second-generation cephalosporins. It has stronger activity against gram-positive cocci such as hemolytic streptococci and pneumococci.

This product is a second-generation cephalosporin antibiotic with a broad-spectrum antibacterial effect. Its bactericidal mechanism is to hinder the synthesis of bacterial cell walls.

Bactericidal cephalosporin antibiotics work by inhibiting bacterial cell wall synthesis. Effective against a broad spectrum of Gram-positive and Gram-negative bacteria, resistant to most beta-lactamases, and sensitive to many pathogenic strains and pathogenic strains associated with hospital-acquired infections, including strains resistant to gentamicin and other aminoglycosides. When used in combination with aminoglycoside antibiotics, the efficacy is at least additive, and there is a clear synergistic effect against some strains.